We show here that the second most common mutation seen in luminal BC (i.e., p53 mutations [53]) is likely to curb other molecule-specific treatments, e.g., an anti-CDK4/6 or mdm2-targeting treatment. This evidence concerns the gene TP53 and breast cancer.